WEBINAR: Bridging the gap: using organ-on-a-chip as an experimental tool to develop (cost) effective therapeutics – Tuesday, 26 September 2023

cnb887 dtr webinar promo bar v1 |
Register here
cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo cn-bio-organ-on-a-chip-logo
  • Products
    • Explore our solutions


      PhysioMimix® products enable you to recreate complex human biology and accurately predict human drug responses

      PhysioMimix OOC

      PhysioMimix OOC systems
      Learn more

      Consumables

      • Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
      Learn more

      Models

      • Single-organ models
      • Liver-on-a-chip model
      • Multi-organ models

      Support packages

      • PhysioMimix® support packages
  • Applications
    • Discover the applications


      Investigate the application areas that our PhysioMimix® products and services support

      Learn more

      Disease modeling

      • Non-Alcoholic Steatohepatitis
      • Hepatitis B
      • COVID-19
      Learn more

      Safety toxicology

      • Drug-induced liver injury
      • Immune-mediated toxicities
      Learn more

      ADME

      • Drug absorption
      • Drug metabolism
      • Drug bioavailability
      Learn more
  • Services
    • Studies as a service


      Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

      Learn more
      NAFLD / NASH icons

      NAFLD / NASH

      Drug-induced liver injury icon

      Drug-induced liver injury

      icon adme |

      ADME

  • Resources
  • Company
    • About us


      Meet the team, explore our culture and discover what to expect when working with us

      CN Bio team photo
      About us

      Latest news

      • A guide to pre-validating cells for use in Organ-on-a-chip assays

      • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems

      • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer

      View all news

      Upcoming Events

      • AASLD 2023

      • EUROTOX 2023

      View all events

      Join the team!

      • Content Marketing Manager

      • Senior Scientist R&D

      View all jobs
  • Contact
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers
  • Contact
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Chat live with an expert

De-risking pre-clinical drug-induced liver injury with organ-on-a-chip

November 10, 2021

Drug-induced liver injury (DILI) is a potential complication of nearly all classes of medication. It’s not at all uncommon for DILI to pass undetected during pre-clinical drug development or to be first identified in the clinic where it can halt trials pending further investigations. In many cases, there’s little to worry about, as typically, ceasing the medication stops the DILI effect but it’s a startling fact that 750 FDA approved drugs are known to have at least some degree of DILI risk [Thakkar et al., 2017] and many potential new drugs are not approved due to excessive DILI risk.

Indeed, DILI remains a leading cause of drug failures in both clinical trials and post-approval. In some severe cases, there have been fatalities, including during trials of fialuridine, or post-approval, The case cost Merck dearly in both legal settlements and reputational damage.

It is therefore clear that we must address the underlying reasons for so many negative surprises in toxicology screening and explore how the industry can overcome this uncertainty. For attrition rates to fall, potential DILI liabilities in humans need to be identified earlier in the pre-clinical discovery pipeline rather than simmering undetected. Doing so would allow promising drugs to return to the drawing board to “engineer out” their issues. It would also enable companies to minimize the risk of expensive problems further down the line. To de-risk more efficientlya number of challenges must be tackled, including:

  • Animal studies falsely identifying toxic drugs as safe and labeling useful drugs as toxic Van Norman 2019. Toxicologists need to flag where human toxicology may differ from animal toxicology and prove a different mechanism of action.
  • The human relevance of standard in vitro test models needs to be improved such that they behave and respond to drugs in a way that more accurately represents the human body. An increase in human relevancy would, in turn, improve predictivity.
  • Standard in vitro cultured assays lack longevity, making them unsuitable for chronic dosing studies.
  • Standard in vitro test models also lack the sensitivity to report clinically relevant liver function endpoints, such as alanine aminotransferase (ALT) or aspartate transaminase (AST), that could improve the translatability of data between the lab and the clinic.
  • It has been historically challenging to use traditional approaches to screen idiosyncratic responses caused by pre-existing liver disease or genetic susceptibility.
  • For new human-specific drug modalities, animal models are unsuitable for use, and therefore toxicologists must find other ways to provide evidence of their safety.

With the increasing need for more predictive pre-clinical in vitro tools to investigate DILI, recent focus has turned to 3D biology and organ-on-a-chip (OOC) -alternatively referred to as microphysiological systems (MPS)- approaches to culture advanced human in vitro liver models that can overcome these challenges, and drive more informed decision making about which medicines to take into the clinic [Weaver et al 2020].

The in vitro DILI testing workflow

In general terms, every potential drug passes through a cascade of tests in early discovery, starting with simplistic high throughput batch screens for cell viability. The drug is applied to hepatocytes grown in 2D cell culture for a rapid yes/no decision. As we progress into the later discovery pipeline, there has been a sustained drive for assays, often referred to as tier 2 and 3, to be made more phenotypically relevant. At this stage, there are far fewer drugs and concentrations to test This smaller number facilitates the use of lower throughput, more complex 3D tissue models that provide in-depth, multi-endpoint mechanistic insights. Through their adoption, researchers can improve the scope of what’s possible in vitro and the predictive power of assays.

Although 3D hepatocyte models are advantageous over 2D, we know that incorporating fluidic flow to mimic the bloodstream is critical to forming and maintaining liver tissues. It extends culture longevity from days to weeks, and enables 3D models to move closer to functioning as living human organs. Flow allows researchers to build up a picture not just of acute effects but more prolonged chronic consequences of toxicity and the sensitivity to detect DILI is also enhanced

Some 3D solutions are available in 96/384-well formats, ,. Whilst first batch screens in 2D typically pick up about a third of the issues, a more complex study from InSphero and AstraZeneca using their 3D primary human hepatocyte and non-parenchymal cell spheroid assay identified up to 60% of DILI positive compounds (Procter et al., 2017). However, 40% remain undetected, so how can we chip away at this number even further?

Gaining more relevant information through ‘flow‘

Category iconBlog

Primary Sidebar

Other recent news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023
  • CN Bio appoints Dr. Samantha Macro as Chief Financial Officer June 6, 2023
  • Immune-mediated DILI – Predicting the unpredictable! March 16, 2023

Speak to our experts

Speak directly with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Terms | Regulatory | Accessibility

Product Recycling

©2023 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • A guide to pre-validating cells for use in Organ-on-a-chip assays September 5, 2023
  • CN Bio and LifeNet Health LifeSciences partner to supply validated primary human cells for microphysiological systems September 5, 2023
  • CN Bio appoints Dr. Tomasz Kostrzewski as Chief Scientific Officer August 30, 2023

Upcoming events

AASLD 2023 November 10-14, 2023

EUROTOX 2023 September 10-13, 2023